Ifupinostat Hydrochloride

盐酸伊吡诺司他

Report date: 2025/10/20 14:43:38
NMEFirst In Class

Base Information

Drug NameIfupinostat Hydrochloride
Drug Alias Name双利司他双替尼他贝特琳BEBT-908CUDC-908
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPI3-kinase class I inhibitorsHistone deacetylase inhibitors
TargetsPI3-kinase class IHistone deacetylase
Therapy Area/IndicationsMetastatic breast cancerLarge B Cell LymphomaSolid tumours +[15] 
Global Approved IndicationsLymphoma, Large B-Cell, Diffuse
Approved Indications in ChinaLymphoma, Large B-Cell, Diffuse
Original Approved Country/TerritoryMainland China
Original Approved Date2025/06/30
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesGuangzhou BeBetter Medicine Technology Co
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesGuangzhou BeBetter Medicine Technology Co
Inactive CompaniesN/A
Active IndicationsMetastatic breast cancerLarge B Cell LymphomaSolid tumours +[12] 
Inactive IndicationsMultiple MyelomaCarcinoma, Renal CellLymphoma

Other Information

ATC CodeN/A
Related LinksN/A